To include your compound in the COVID-19 Resource Center, submit it here.

Sobi buying Novimmune assets as it refocuses R&D

Less than a year after gaining an exclusive worldwide license for Gamifant emapalumab from Novimmune, Sobi is acquiring a newco formed around the hematology therapy for CHF515 million ($519.2 million) and

Read the full 312 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers